Seres Therapeutics Inc expected to post earnings of 53  cents a share - Earnings Preview

Seres Therapeutics

28/07/2023 18:57

* Seres Therapeutics Inc  MCRB.OQ   MCRB.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 1
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 10,236.9% increase in revenue to $125.696 million from $1.22
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Seres Therapeutics
Inc is
for earnings of 53 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Seres
Therapeutics Inc is $12​, above​ its last closing price
of $4.42. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.56       -0.55      -0.57     Missed  -3.8
 Dec. 31 2023  -0.30       -0.46      -0.54     Missed  -16.1
 Sep. 30 2022  -0.50       -0.47      -0.49     Missed  -4.5​
 Jun. 30 2022  -0.59       -0.60      -0.70     Missed  -17.4
 ​​Mar.        -0.54       -0.52      -0.61     Missed  -16.4
 31 2022                                                
 Dec. 31 2021  -0.44       -0.44      -0.52     Missed  -19.1​
 Sep. 30 2021  -0.48       -0.46      0.72      Beat    255.6
 Jun. 30 2021  -0.36       -0.37      -0.53     Missed  -42.5
 This summary was machine generated July 28 at 17:57 GMT.  All
figures in US dollars  unless otherwise stated